System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Ismaela Anna Vascotto is an expert in Oncology at Careggi University Hospital (Italy). Ismaela Anna Vascotto has authored 23 publications, the most recent in 2026. SLR score: 90 (community average: 125). How the SLR is computed.

LeadR Profile

Ismaela Anna Vascotto Careggi University Hospital Italy
90 ScienceLeadR Reputation 90

Unlock

Register Login
Network Map

Oncology

Subspecialties: Urology - Immunology - Genetics

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2023 - 2026
Source: PubMed

University of Florence

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 23

Citations

Citations: 8 1st author: 2 Last author: 0 Unique author: 0

Main journals

J Clin Oncol 3
Clin Genitourin Cancer 2
Front Immunol 2
Ann Oncol 1
Biomolecules 1

Best Journals

J Clin Oncol 3
Ann Oncol 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Immune Checkpoint Inhibitor-Related Pneumonitis in Renal Cell Carcinoma: Clinical Features, Mechanisms, and Lessons from Lung Cancer.
PMID 42650785 — cells, lung, neoplasms, carcinoma, renal cell, immunotherapy, immune checkpoint inhibitors, lung neoplasms		Biomolecules20260
Effectiveness and safety of avelumab maintenance in patients aged ≥75 years with advanced urothelial cancer: a sub-analysis of the meet-URO 25 (MALVA) study.
PMID 42367804 — safety, neoplasms, maintenance, immunotherapy, aged, neoplasm metastasis, immune system diseases, therapeutics		Front Immunol20260
Prostate-Specific Membrane Antigen Positron Emission Tomography and Radiometabolic Therapies in Metastatic Castration-Resistant Prostate Cancer.
PMID 42330367 — tomography, positron-emission tomography, neoplasms, prostate, prostatic neoplasms, castration, therapeutics, medical oncology, membranes		J Clin Oncol Top journal20261
Clinical and pathological predictors of early recurrence after neoadjuvant cisplatin gemcitabine in muscle invasive bladder cancer in the RealBLADDER study.
PMID 42321365 — urinary bladder, urinary bladder neoplasms, muscles, neoplasms, cystectomy, therapeutics		Sci Rep20260
Case Report: Niraparib-abiraterone in HRR-mutated metastatic castration-resistant prostate cancer: clinical insights from five cases.
PMID 42125687 — genes, safety, progression-free survival, prednisone, neoplasms, abiraterone acetate, prostate, acetates, aged, recombinational dna repair, prostatic neoplasms, castration, therapeutics		Front Oncol20260

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS